Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2021-02-04 Capital/Financing Update
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext annonce un financement de 11 millions d'euros par le biais d'une augmentation de capital souscrite au bénéfice d'actionnaires existants et d'une émission d'obligations convertibles auprès d'i
Capital/Financing Update Classification · 1% confidence The document explicitly announces a financing operation involving an equity capital increase ('augmentation de capital') and the issuance of convertible bonds ('obligations convertibles'). This directly relates to the company's fundraising and capital structure changes. The key terms are 'financement', 'augmentation de capital', and 'obligations convertibles'. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA), as it details the terms and structure of the financing itself.
2021-02-04 French
Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
Regulatory Filings Classification · 1% confidence The document is titled "Pharnext Provides an Update on its Pivotal Clinical Development Program..." and is dated February 1, 2021. It discusses clinical trial progress (PREMIER trial, Phase III Extension Study), regulatory interactions (FDA IND, SPA), and provides future guidance on when interim data will be reported (Q2 2021). This content structure—providing operational and clinical updates rather than full financial statements (like 10-K or IR) or formal voting results—is characteristic of a press release announcing corporate developments. Since it is not a formal regulatory filing like a 10-K, nor a transcript, nor a specific financial announcement like an Earnings Release (ER) which focuses on period results, it best fits the general category for corporate news updates. Given the options, this is a general corporate announcement that doesn't fit the highly specific categories like DIV, DIRS, or CAP. It is most closely aligned with a general Regulatory Filing (RNS) if it were a mandatory filing, but since it reads like a proactive press release detailing operational progress, and there is no specific category for 'Clinical Update Press Release', the most appropriate fallback category for a non-standard, non-financial-results announcement is RNS, or potentially ER if it were interpreted as a preliminary results announcement, but it focuses more on trial status than financial performance highlights. Given the focus on clinical trial milestones and regulatory progress, RNS (Regulatory Filings/General Announcement) is the most suitable general category for this type of corporate communication that isn't a core financial report or a specific event announcement.
2021-02-01 English
Pharnext fait le point sur son programme de développement clinique pivot dans la maladie de Charcot-Marie-Tooth de type 1A (CMT1A)
Regulatory Filings Classification · 1% confidence The document is a press release dated February 1, 2021, providing an update on the clinical development program for the drug candidate PXT3003, specifically mentioning progress towards initiating the Phase III pivot trial (PREMIER) in the US (IND application with the FDA) and providing interim data timelines for an extension study. It details trial design, regulatory interactions (FDA SPA), and provides background on the disease and the drug. This content structure—a detailed, time-sensitive update on clinical trials, regulatory milestones, and future data releases, issued via a press release format—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update rather than a summary of financial performance (ER) or a miscellaneous filing (RNS), and given the focus on clinical/regulatory progress, it most closely aligns with a general corporate update. However, because it is a detailed announcement of operational progress and future data points, and not a formal statutory report (like 10-K or IR), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific operational announcements not covered elsewhere. It is not a short announcement pointing to an attached report (RPA).
2021-02-01 French
Pharnext: Shareholder Letter
Management Reports Classification · 1% confidence The document is explicitly titled as a 'Letter to Shareholders from its Chief Executive Officer, Dr. David Horn Solomon' and discusses key operational, clinical, and management changes that occurred during the year 2020, including FDA guidance, board appointments, and future financing plans. This format, delivered by the CEO to shareholders, is characteristic of a formal shareholder communication, often accompanying or summarizing an Annual Report, but it is not the full Annual Report (10-K) itself. Since it is a direct communication from management to shareholders detailing performance and strategy, it aligns best with the content typically found in an Investor Presentation (IP) or a high-level summary, but the specific format as a 'Letter to Shareholders' is often included within or closely related to the Annual Report cycle. Given the content focuses heavily on strategy, clinical pipeline (PXT3003), management changes, and future funding needs, it functions as a detailed update for investors. However, the document structure strongly suggests it is a standalone communication, which often falls under Investor Presentation (IP) or sometimes a specific section of an Annual Report. Since it is a detailed narrative update rather than just a presentation deck, and it is not a formal regulatory filing like 10-K or IR, 'Investor Presentation' (IP) is the most fitting category for this type of detailed CEO update letter, although it could also be considered part of the broader Annual Report documentation if it were attached to one. Given the context of a CEO letter summarizing the year's progress and outlook, IP is the best fit among the provided options for a detailed, non-statutory report update.
2020-10-29 English
Pharnext: Lettre aux Actionnaires
Regulatory Filings Classification · 1% confidence The document is a 'Lettre aux Actionnaires' (Letter to Shareholders) from Pharnext SA. It provides a strategic update from the CEO regarding clinical trial progress (PXT3003), management changes, board appointments, and future financing plans. It does not contain formal financial statements, nor is it a regulatory filing or a specific report type like a 10-K or IR. It functions as a corporate communication/update to shareholders, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement in the absence of a more specific category for shareholder letters. FY 2020
2020-10-29 French
Pharnext announces 2020 half-year results
Earnings Release Classification · 1% confidence The document is a press release titled 'Pharnext announces 2020 half-year results'. It provides a summary of financial performance for the first half of 2020, including a table of financial information (IFRS), and discusses key events, corporate governance, and cash-in operations. While it contains financial data, it is a summary announcement rather than the full, comprehensive interim report itself, as evidenced by the statement 'Complete financial statements are available on the Pharnext website'. Therefore, it is classified as an Earnings Release (ER). H2 2020
2020-10-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.